Shamburg News · 8-K filed Nov 17, 2026, 5:29 PM EST

Inhibrx Announces Updated Clinical Data for Ozekibart in Relapsed Ewing Sarcoma

INBX · Inhibrx Biosciences, Inc.

  • Other event
  • Materiality: medium

Inhibrx Biosciences announced updated Phase 1/2 expansion study data for ozekibart (INBRX-109) combined with irinotecan and temozolomide in relapsed or refractory Ewing sarcoma, to be presented at the CTOS 2026 Annual Meeting. Among 51 response-evaluable patients as of the September 18, 2026 data cutoff, the overall response rate was 62.7% and the disease control rate was 86.3%, with median progression-free survival of 6.0 months. The press release was issued November 17, 2026 and furnished as Exhibit 99.1.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Items 8.01, 9.01, accession 0002007919-26-000063.

Written from the filing by Shamburg Markets. Figures are as reported by the company.